Prof. Dr. Gerold Schuler



Organisationseinheit


Lehrstuhl für Haut- und Geschlechtskrankheiten


Preise / Auszeichnungen


2010 : Mitgliedschaft Nationale Akademie der Wissenschaften Leopoldina
1998 : Mitgliedschaft Österreichische Akademie der Wissenschaften


Publikationen (Download BibTeX)

Go to first page Go to previous page 1 von 10 Go to next page Go to last page

Riethdorf, S., Hildebrandt, L., Heinzerling, L., Heitzer, E., Fischer, N., Bergmann, S.,... Pantel, K. (2019). Detection and Characterization of Circulating Tumor Cells in Patients with Merkel Cell Carcinoma. Clinical Chemistry, 65(3), 462-472. https://dx.doi.org/10.1373/clinchem.2018.297028
Krueckel, A., Moreira, A., Froehlich, W., Schuler, G., & Heinzerling, L. (2019). Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma. BMC Cancer, 19. https://dx.doi.org/10.1186/s12885-019-5384-z
Moreira, A., Loquai, C., Pfoefer, C., Kaehler, K.C., Knauss, S., Heppt, M.V.,... Heinzerling, L. (2019). Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. European journal of cancer, 106, 12-23. https://dx.doi.org/10.1016/j.ejca.2018.09.033
Moreira, A., Gross, S., Kirchberger, M.C., Erdmann, M., Schuler, G., & Heinzerling, L. (2019). Senescence markers: Predictive for response to checkpoint inhibitors. International Journal of Cancer, 144(5), 1147-1150. https://dx.doi.org/10.1002/ijc.31763
Simon, B., Wiesinger, M., Maerz, J., Wistuba-Hamprecht, K., Weide, B., Schuler-Thurner, B.,... Uslu, U. (2019). The transfection of natural killer T cells with a tumor-antigen specific chimeric antigen receptor (CAR) for melanoma immunotherapy. In EXPERIMENTAL DERMATOLOGY (pp. E56-E57). HOBOKEN: WILEY.
Teramoto, Y., Keim, U., Gesierich, A., Schuler, G., Fiedler, E., Tueting, T.,... Garbe, C. (2018). Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. British Journal of Dermatology, 178(2), 443-451. https://dx.doi.org/10.1111/bjd.15803
Moreira, A., Kirchberger, M.C., Toussaint, F., Erdmann, M., Schuler, G., & Heinzerling, L. (2018). Anti-PD-1 Therapy in SUFU mutant Patients with Gorlin-Goltz Syndrome. (pp. 72-73).
Hoyer, S., Eberlein, V., Babalija, L., Gerer, K., Walter, L., Schuler, G.,... Dörrie, J. (2018). BRAF and MEK inhibitors change human immune cell phenotype and function; possible consequences for combination therapy. (pp. E22-E22).
Dörrie, J., Babalija, L., Hoyer, S., Gerer, K.F., Schuler, G., Heinzerling, L., & Schaft, N. (2018). BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy. International Journal of Molecular Sciences, 19(1). https://dx.doi.org/10.3390/ijms19010289
Kirchberger, M.C., Schilling, B., Haferkamp, S., Boßerhoff, A.K., Schuler, G., & Heinzerling, L. (2018). Can checkpoint inhibitor therapy improve response to chemotherapy? Journal of Cancer Research and Clinical Oncology, 144(1), 183-185. https://dx.doi.org/10.1007/s00432-017-2546-8

Zuletzt aktualisiert 2016-08-06 um 02:00